DOCSLIB.ORG

Glossary of Drug Names Y> \C British Approved Name U.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glossary of Drug Names Y> \C British Approved Name U.S Glossary of Drug Names Y> \C British Approved Name U.s. Adopted Name British Trade Name U.S. Trade Name 00 adrenaline epinephrine Adrenalin amiloride amiloride Midamor Colectril aminophylline aminophylline Theodrox, Aminodur Lixaminol amiphenazole Daptazole amoxycillin amoxicillin Amoxil Amoxil, Larocin ampicillin ampicillin Penbritin Penbritin, etc. bendrofluazide bendroflumethiazide Aprinox, Neonaclex, etc. Benuron, Naturetin bumetanide bumetanide Burinex carbimazole carbimazole Neomercazole Methimazole chlormethiazole clomethiazole edisylate Heminevrin chlorthalidone chlorthalidone Hygroton Hygroton chlorothiazide chlorothiazide Saluric Diuril choline theophyllinate oxtriphylline Choledyl Choledyl clofibrate clofibrate Atromid-S Atromid-S clonidine clonidine Catapres Catapres, Combipres clopamide clopamide Brinaldix cloxacillin cloxacillin Orbenin Tegopen cyclopenthiazide cyclopenthiazide Navidrex debrisoquine debrisoquine Declinax deslanoside Cedilanid-D C) Q diazepam diazepam Valium Valium CIl diazoxide diazoxide Eudemine Hyperstat CIl digitoxin digitoxin Digitaline Crystodigin, Digitaline ~ Nativelle Nativelle, Purodigin 0 digoxin digoxin Lanoxin Lanoxin 0'"' edrophonium edrophonium Tensilon Tensilon 2 ethacrynic acid ethacrynic acid Edecrin CIQ Edecrin Z frusemide: furosemide Lasix Lasix ~ gitalin GitaJigin a /D CIl glyceryl trinitrate ni troglycerin Trinitrin Nitrol C) 0 guanethidine guanethidine Ismelin Ismelin - '" hydrallazine hydralazine Apresoline Apresoline '"III .:! hydrochlorothiazide hydrochlorothiazide Esidrex Hydrodiuril, Oretin 0 hydroflumethiazide hydroflumethiazide Naclex Diucardin, Saluron ..... isoprenaline isoproterenol Saventrine Isuprel t:I lanatoside-C lanatoside-C Cedilanid Cedilanid (Jqa levodopa L-dopa Larodopa, Brocadopa, Levodopa, Bendopa, Z Sinemet, Madopar Dopar, Larodopa III lignocaine lidocaine Xylocaine Xylocaine III51 mefruside mefruside Baycaron '" metaraminol metaraminol Aramine Aramine methyldopa methyldopa Aldomet Aldomet minoxidil minoxidil nikethamide nikethamide Coramine Coramine ouabain ouabain Ouabaine Ouabain oxprenolol oxprenolol Trasicor phenylbutazone phenylbutazone Butazolidin Butazolidin phenylephrine phenylephrine Neosynephrine Neosynephrine phenytoin phenytoin Epanutin Dilantin pindolol Visken practolol practolol Eraldin procainamide procainamide Pronestyl Pronestyl propanolol propanolol Inderal Inderal proxyphylline Thean quinidine quinidine Quinidine Sulfate reserpine reserpine Serpasil Serpasil, etc. salbutamol salbutamol Ventolin Ventolin spironolactone spironolactone Aldactone Aldactone thioridazine thioridazine Melleril Mellaril triamterene triamterene Dytac Dyrenium \.» warfarin warfarin Marevan Coumadin, etc. \D \D Index A wave, 228 Aneurysm Accessory bundles, 78 aortic, 160, 243, 378 Acetyldigoxin, 267 coronary, 193 Acetylstrophanthidin, 267, 272 dissecting, 51, 157, 241, 378 Acidosis, 216, 223 ventricular, 15, 302, 388-390 l3-Adrenergic blockade, 105, 186-188, Aneurysmectomy, 344, 390 246, 306, 322, 351 Angina pectoris, 127 Age changes anemia, 195, 263 baroreceptor function, 104-106 aortic valve disease, 195, 237, 377- blood pressure, 102-104, 145-147 378 cardiac output, 81-98 hypothyroidism, 262 cerebral blood flow, 107-109 ischemic heart disease, 3, 194-195, conduction system, 57-61,64-67 263, 299, 323, 338, 383-384, drug handling, 185, 257, 275, 318-319 386,388 myocardium, 12-13, 58-59 rheumatic heart disease, 232 valves, 13 syphilitic aortitis, 195 Albuminuria, 165 Angiocardiography, 141, 236 Alcoholism, 24, 121 Angiography, 370, 390 Aldosterone, 181, 280, 283 Angiotensin, 104 Aldosterone antagonist, 224 Ankylosing spondylitis, 49, 76, 241 Alkaline phosphatase, 19 Annuloplasty, 374, 382 Alkalosis, 283, 293 Antacids, 272 Alveolocapillary block, 226 Antibiotics, 44-45, 184, 202, 221, Amiloride, 186, 280, 283, 285 252,256-257,294,355 Aminophylline, 233-234, 285 Anticholinergic drugs, 272 Amiphenazole, 224 Anticoagulants, 234, 293-294, 305, Amoxycillin, 222 339,374,381,386 Ampicillin, 222 Antihypertensive therapy, 144, 158, Amyloid, amyloidosis, 11, 17,52,59, 173-174, 184-185, 190 68-69,121 Antinuclear antibody, 322 Anacrotic pulse, 237 Anxiety state, 328 Analgesics, 305 Aorta Anemia aneurysm, 160, 243, 378 angina, 195, 263 coarctation, 13, 391 bacterial endocarditis, 258 dilatation, 51, 243-244 cardiac failure, 263, 288 ~ssection,51, 157,241,378 cardiac pathology, 13, 24 rupture, 241 methyldopa, 187 unfolding, 137 401 402 Index Aortic incompetence Asthma, 186, 199, 312,323 ankylosing spondylitis, 76 Asymmetrical septal hypertrophy, 21 bacterial endocarditis, 254 Asystole, 307, 328, 347, 350 clinical features, 241-244 Atheroma, Atherosclerosis, 15, 22, murmur, 134, 238, 254 159, 183 pathology, 49-51 Atrial dilatation, 36, 233, 244, 388 pulse, 128 Atrial fibrillation rheumatic, 232 bacterial endocarditis, 254 surgery, 378-381, 385 cardiac infarction, 195, 203, 300- syphilitic, 242-243, 294 312 Aortic stenosis diagnosis, 131, 327-328, 330 clinical features, 134, 237-241, 348 epidemiology, 8 epidemiology, 6 mitral valve disease, 232-234, 236 murmur, 134 paroxysmal,335 pathology, 13, 28-32,73,77 pathology, 68-69, 316 pulse, 128, 349 pericardial disease, 264 rheumatic, 232, 376 physiology, 318 surgery, 376-382 prognosis, 294 Aortic valve thyrotoxicosis, 260-261 bicuspid, 13, 376, 391 treatment, 270-271, 275, 319, 322- calcification, 11, 239, 245, 250 323,335,353,374 cusp prolapse, 241 Atrial flutter rupture, 46,241 cardiac infarction, 203, 300, 302, quadricuspid, 13 306 replacement, 378-382 pathology, 316 ring, 49-51, 73, 350 pulmonary embolism, 335 sclerosis, 26, 49, 134, 239, 250, treatment, 319, 323, 327, 330, 335 348, 378 Atrial hypertrophy, 129 vegetations, 259 Atrial myocardium, 17, 58, 68, 75 Aortitis, 50, 138, 195, 241 Atrial myxoma, 24, 236 Aortopathy,50 Atrial pacing, 374 Apexcardiography, 139-140 Atrial septal defect, 13, 130, 133, Arrhythmia, 12, 134, 180, 228, 315- 245, 390 346 Atrial systole, 129, 357 atrial, 58, 68, 75, 316, 380 Atrial tachycardia, 271, 322, 327-328, cardiac infarction, 195, 300, 302, 331 304-305 Atrial thrombosis, 138, 234 nodal, 203, 339 Atrioventricular block (see Heart block) sino-atrial, 17 Atrioventricular node sinus, 324 anatomy, 60-61 supraventricular, 306, 321, 326,329 arrhythmia (See Junctional, etc.) Arterial elasticity, 147 physiology, 317 Arterial embolism, 48, 232, 244,.388 Atrophy, brown, 12 Arterial peo2 (See also Hypercapnia), Atropine, 113, 275, 305-307, 328, 98,218-219,221 333, 345 Arterial P02 , 98, 305 Autonomic nervous system, 118, 316 Arterial pulse, 128, 316 Arterial resistance, 270 Bacteremia, 44, 255 Arteriography, 309, 383 Bacterial endocarditis, 44-47, 250-279 Arteritis, 193 aortic valve disease, 46, 241,250 Ascites, 219, 261, 264 clinical features, 236, 252-257 Index 403 Bacterial endocarditis (cont'd) Bradycardia (cont'd) enterococcal, 45, 251 pacemaker failure, 358 mucoid degeneration of mitral reflex, 104-106 valve, 40-41, 250 Bradytachy syndrome, 328, 353 pathology, 44-47 Brain (See Cerebral) pneumococcal, 46 Bronchitis, 6, 186, 216, 221, 225,232, prognosis, 258-259 287,310 rheumatic heart disease, 45, 233, Bronchodilators, 222-223 250 Brucella,31 staphylococcal, 45-46,251-252,259 Bundle branch streptococcal, 45,251-252, 259 anatomy, 33, 61-68 treatment, 257-259 pathology, 69-77 Bacteriuria, 181 Bundle branch block Ballistocardiography, 141 left, 8, 77, 140,180,195,238,302, Barbiturates, 121, 228 344,352 Baroreceptors, 103-120, 241, 270 right, 8, 77,132,135,195,344, Basal metabolic rate, 85, 95 352 Bed rest, 289, 294 Bundle of His Belladonna, 328 accessory, 78 Bendrofluazide, 186 anatomy, 33, 61-68 Blood culture, 45, 236, 255 electrography, 135,353 Blood flow, pathology, 69-78 cerebral, 95, 104, 107, 127,156, 317 Calcification skeletal muscle, 95 aortic annulus, 11 skin, 95 aortic knuckle, 137 splanchnic, 95 aortic valve, 11, 25-26, 29, 134,2.39, Blood gases (See also Arterial PC02 , 245,250,379 P02 , Hypercapnia, Hypoxia), ascending aorta, 138, 243 215,221,371,380 cardiac aneurysm, 15, 138 Blood pressure (See also Hyperten- metastatic, 35 sion, Hypotension) mitral annulus, 11, 32, 47, 73, 235, cardiac infarction, 300 250,350 casual, 154-156 mitral valve, 25,42 diastolic, 152, 180 pericardium, 138, 264 digitalis, 284 Calcium, 269, 273, 309, 316-317 exercise, 87 Cannon wave, 129 hyponatremia, 293 Capillaries, pulmonary, 88, 92-93, normal, 102-103, 128, 144-145, 214,372,377 177-179 Capillary pulsation, 241 regulation, 101-123 Carbimazole, 261 systolic, 152-177 Carbon dioxide (See Arterial PC02 , Blood transfusion, 263 Hypercapnia) Blood volume, 93, 97, 115 Carcinoid heart disease, 51, 245 Bradyarrhythmia, 237, 272, 345 Carcinoma, 24,47-48,76,121,251, Bradycardia 253,259,263 (j-adrenergic blockade, 186, 351 Cardiac arrest, 321, 346 cardiac infarction, 201, 204, 304, Cardiac aneurysm, 15, 51, 138, 157, 307 241,378 complete heart block, 347-349 Cardiac catheterisation, 81, 91, 97, digitalis, 274-275 141,239,387 404 Index Cardiac failure (see Congestive heart Catecholamines, 113, 118, 120, 181, failure, Left ventricular failure) 322,351 Cardiac impulse, 129, 219 Cerebral Cardiac index, 81, 377 anoxia, 200 Cardiac infarction (See also Ischemic blood flow, 95,104,107,127,156, heart disease) 288,317,327 arrhythmias, 195, 300, 302, 304- embolism, 52 305,327,340 infarction, 103, 145, 158, 160,164- complications, 15-16, 297-312 165,180,184,201-202,333, congestive heart failure, 288, 292 381 coronary care, 297-312 ischemia, 348 epidemiology, 5, 8, 160 metabolism, 107 heart block, 75-77,350, 357 vascular disease,
Load more

Recommended publications
  • Use of ²-Blockers and Risk of Fractures
    ORIGINAL CONTRIBUTION Use of ␤-Blockers and Risk of Fractures Raymond G. Schlienger, PhD, MPH Context Animal studies suggest that the ␤-blocker propranolol increases bone for- Marius E. Kraenzlin, MD mation, but data on whether use of ␤-blockers (with or without concomitant use of thiazide diuretics) is associated with reduced fracture risk in humans are limited. Susan S. Jick, DSc Objective To determine whether use of ␤-blockers alone or in combination with thia- Christoph R. Meier, PhD, MSc zides is associated with a decreased risk of fracture in adults. Design, Setting, and Participants Case-control analysis using the UK General Prac- TUDIES HAVE SUGGESTED THAT tice Research Database (GPRD). The study included 30601 case patients aged 30 to the sympathetic nervous sys- 79 years with an incident fracture diagnosis between 1993 and 1999 and 120819 con- tem has a catabolic effect on trols, matched to cases on age, sex, calendar time, and general practice attended. bones.1-4 In vitro data show that Main Outcome Measures Odds ratios (ORs) of having a fracture in association Sadrenergic agonists stimulate bone re- with use of ␤-blockers or a combination of ␤-blockers with thiazides. sorption in organ culture of mouse cal- Results The most frequent fractures were of the hand/lower arm (n=12837 [42.0%]) variae.4 Chemical sympathectomy with and of the foot (n=4627 [15.1%]). Compared with patients who did not use either guanethidine, a sympathetic neuro- ␤-blockers or thiazide diuretics, the OR for current use of ␤-blockers only (Ն3 pre- toxic agent, impairs bone resorption by scriptions) was 0.77 (95% confidence interval [CI], 0.72-0.83); for current use of thia- inhibiting preosteoclast differentiation zides only (Ն3 prescriptions), 0.80 (95% CI, 0.74-0.86); and for combined current ␤ and disturbing osteoclast activation in use of -blockers and thiazides, 0.71 (95% CI, 0.64-0.79).
    [Show full text]
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Comprehensive Screening of Diuretics in Human Urine Using Liquid Chromatography Tandem Mass Spectrometry
    id5246609 pdfMachine by Broadgun Software - a great PDF writer! - a great PDF creator! - http://www.pdfmachine.com http://www.broadgun.com AAnnaallyyttiiccaaISllS N : 0974-7419 Volume 13 Issue 7 CCHHEEAnMM IndIIiSaSnT TJoRuRrnYaYl Full Paper ACAIJ, 13(7) 2013 [270-283] Comprehensive screening of diuretics in human urine using liquid chromatography tandem mass spectrometry Shobha Ahi1, Alka Beotra1*, G.B.K.S.Prasad2 1National Dope Testing Laboratory, Ministry of Youth Affairs and Sports, CGO Complex, Lodhi Road, New Delhi,-110003, (INDIA) 2SOS in Biochemistry, Jiwaji University, Gwalior, (INDIA) E-mail : [email protected] ABSTRACT KEYWORDS Diuretics are drugs that increase the rate of urine flow and sodium excretion Doping, diuretics; to adjust the volume and composition of body fluids. There are several LC-MS/MS; WADA; major categories of this drug class and the compounds vary greatly in Drugs of abuse. structure, physicochemical properties, effects on urinary composition and renal haemodynamics, and site mechanism of action. Diuretics are often abused by athletes to excrete water for rapid weight loss and to mask the presence of other banned substances. Because of their abuse by athletes, ’s (WADA) diuretics have been included in the World Anti-Doping Agency list of prohibited substances. The diuretics are routinely screened by anti- doping laboratories as the use of diuretics is banned both in-competition and out-of-competition. This work provides an improved, fast and selective –tandem mass spectrometric (LC/MS/MS) method liquid chromatography for the screening of 22 diuretics and probenecid in human urine. The samples preparation was performed by liquid-liquid extraction. The limit of detection (LOD) for all substances was between 10-20 ng/ml or better.
    [Show full text]
  • Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
    Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
    [Show full text]
  • New Prohibited Substances Addition to Procedures Using Triple Quadrupole LC/MS2 Technique
    Poster MANFRED DONIKE WORKSHOP Pop V, Bican G, Pop A, Lamor M, Zorio M New prohibited substances addition to procedures using triple quadrupole LC/MS2 technique Romanian Doping Control Laboratory, Bucharest, ROMANIA Abstract New substances are added each year to the different classes of substances of WADA’s Prohibited List and have to be included in the test menu of each accredited doping control laboratory. For the analysis of some of these compounds the technique of choice is the LC/MS2 technique. Furthermore, with the decrease of MRPL levels, for stimulants from 500 ng/mL to 100 ng/mL and for narcotics from 200 ng/mL to 50 ng/mL, beginning from the entering in force on 1 January 2013 of the new WADA Technical Document TD2013MRPL, some of the compounds analyzed by the current GC/MS based procedure for stimulants and narcotics needed to be transferred to the LC/MS2 based procedure in order to lower their limit of detection. This paper-work presents the optimal conditions for preparation, separation and identification of new substances introduced to the LC/MS2 technique based procedures during the year 2012. Introduction Liquid chromatography coupled with mass spectrometry is increasingly used in doping control laboratories [1]. The current work presents the optimization of the LC/MS2 detection parameters and the introduction of the prohibited substances in the existent procedures, depending on the characteristics of the studied compounds. The studied compounds are benzthiazide, cyclopenthiazide, cyclothiazide, epitizide, hydroflumethiazide and polythiazide (thiazide diuretic compounds), tramadol and its O-desmethyl metabolite (narcotic compound from the monitoring program [2]), cyclazodone, pentetrazole, prolintane, propylhexedrine and selegiline (stimulants transferred from the GC/MS- to the LC/MS2-based procedure due to the decreasing of the MRPL levels for stimulants and narcotics [3]).
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Proxyphylline Item No. 20937 CAS Registry No.: 603-00-9 Formal Name: 3,7-dihydro-7-(2-hydroxypropyl)-1,3- N dimethyl-1H-purine-2,6-dione O N Synonym: NSC 163343 C H N O MF: 10 14 4 3 N FW: 238.2 N Purity: ≥98% O UV/Vis.: λmax: 273, 324 nm Supplied as: A crystalline solid OH Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Proxyphylline is supplied as a crystalline solid. A stock solution may be made by dissolving the proxyphylline in the solvent of choice. Proxyphylline is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of proxyphylline in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of proxyphylline can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of proxyphylline in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Proxyphylline is a methylxanthine derivative that has bronchodilatory actions.1 It has also been reported 2 to have vasodilatory and cardiac stimulatory effects.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • 12.2% 122,000 135M Top 1% 154 4,800
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE We are IntechOpen, provided by IntechOpen the world’s leading publisher of Open Access books Built by scientists, for scientists 4,800 122,000 135M Open access books available International authors and editors Downloads Our authors are among the 154 TOP 1% 12.2% Countries delivered to most cited scientists Contributors from top 500 universities Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI) Interested in publishing with us? Contact [email protected] Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com Chapter A Detail Chemistry of Coffee and Its Analysis Hemraj Sharma Abstract This review article highlights the detailed chemistry of coffee including its components; chemical constituents like carbohydrates, proteins, lipids, and caf- feine; aromatic principles; oil and waxes; and minerals and acids. The high extent of caffeine can be found in the coffee plants; hence, in the second part of the study, various analytical methods are designed for the proper identification, separation, optimization, purification, and determination of caffeine present in coffee, tea, and marketed coffee. These analytical methods are appropriated for the separation and quantification of caffeine. The various analytical methods include spectroscopy methods like UV, IR, and NMR spectroscopy; chromatographic methods like paper, TLC, column, HPLC, and gas chromatography; and hyphenated techniques like LC–MS, GC–MS, and GC–MS/MS. This article compares and contrasts the amount of caffeine by various analytical methods. Keywords: caffeine, spectrophotometer, chromatography, hyphenated techniques, electrochemical methods 1.
    [Show full text]
  • Effect of Practical Timing of Dosage on Theophylline Blood Levels In
    Arch Dis Child: first published as 10.1136/adc.53.2.167 on 1 February 1978. Downloaded from Archives of Disease in Childhood, 1978, 53, 167-182 Short reports Effect of practical timing of dosage Methods on theophylline blood levels in For the period of the study, the children did not asthmatic children treated with receive tea, which contains theophylline. choline theophyllinate GroupA. These childrenwere given choline theophyll- The bronchodilator effect of theophylline has been inate in a dosage of as near as possible 8 mg/kg per known for over 50 years, but although it has been dose qds (mean 7 9 mg/kg, range 7-2-8 7 mg/kg), widely used both intravenously and rectally in the starting with half the dose on the first day to try and treatment ofacute asthma, its use as an oral broncho- minimise nausea. The doses were given at 0800 h, dilator has been limited by inadequate knowledge of 1300 h, 1700 h, and 2100 h, times considered suitable the correct dosage of the oral preparations. The for administration outside hospital. On the third day therapeutic level of theophylline is generally con- ofthe study serum levels were measured 2 hours after sidered to be between 10 and 20 ,ug/ml (Turner- each dose and before the 0800 h dose the following Warwick, 1957; Jenne et al., 1972), although sub- morning. optimal bronchodilation can be achieved with levels of 5 ,ug/ml or less (Maselli et al., 1970; Nicholson and Group B. These children were given cholinetheophyll- Chick, 1973). Serious toxicity with levels of less than inate in a dosage of as near as possible 10 mg/kg per copyright.
    [Show full text]
  • Pharmaceuticals 2010, 3, 725-747; Doi:10.3390/Ph3030725
    Pharmaceuticals 2010, 3, 725-747; doi:10.3390/ph3030725 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Theophylline Peter J. Barnes National Heart and Lung Institute, Imperial College, London, UK; E-Mail: [email protected]; Tel.: +44-207-351-8174; Fax: +44-207-351-5675. Received: 14 January 2010 / Accepted: 18 March 2010 / Published: 18 March 2010 Abstract: Theophylline (3-methyxanthine) has been used to treat airway diseases for over 70 years. It was originally used as a bronchodilator but the relatively high doses required are associated with frequent side effects, so its use declined as inhaled β2-agonists became more widely used. More recently it has been shown to have anti-inflammatory effects in asthma and COPD at lower concentrations. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes. Through this mechanism theophylline also reverses corticosteroid resistance and this may be of particular value in severe asthma and COPD where HDAC2 activity is markedly reduced. Theophylline is given systemically (orally as slow-release preparations for chronic treatment and intravenously for acute exacerbations of asthma) and blood concentrations are determined mainly by hepatic metabolism, which may be increased or decreased in several diseases and by concomitant drug therapy. Theophylline is now usually used as an add-on therapy in asthma patients not well controlled on inhaled corticosteroids and in COPD patients with severe disease not controlled by bronchodilator therapy.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]